UA Frame EN

Welcome to licensed pharmacies in Poland:

Non-prescription medicines delivery across Europe.

Frequently ordered: potency boosters (sildenafil OTC), quit smoking aids.

Ирина (Anonymous, 94.79.7.) Warszawa 37 days ago

Can Mounjaro be used in oncology?

Is it possible to use the drug in oncology?

1 answer

* required field

You can drag the photo file here.

* required field

Notify of a new answer.
Other messages will not be sent.

Suggested Products

Space for your product

Your product would fit here?

Set up a sponsored products campaign yourself:

Check

Anna Lewandowska Pharmacist, Editor

37 days ago

In oncology, cancer treatment is based on other methods, such as surgery, chemotherapy or radiotherapy, and Mounjaro is not part of standard cancer therapy.

Mounjaro (active substance: tirzepatide) is approved for the treatment of type 2 diabetes and to support weight loss in people who are obese or overweight, but is not indicated or approved for use in cancer therapy.

Although some studies suggest that GLP-1 receptor analogues, such as tirzepatide, may affect the risk of certain cancers, such as colon cancer, Mounjaro is currently not used as an anti-cancer drug and is not approved for such use.

If you wish to use Mounjaro in cancer patients, you should consult a specialist doctor, as this drug has specific indications and contraindications, and its off-label use may be associated with risks and lack of efficacy.

If you need more personalized advice, you can use teleconsultations here:

https://www.gdziepolek.pl/telekonsultacja

The advice is provided in Polish.

Through Gdziepolek, it is possible to book medicines in a selected pharmacy in Polish:

https://www.gdziepolek.pl/produkty/129174/mounjaro-kwikpen-iniekcja/apteki

Appreciate the answerer and highlight the question on the home page
User questions and answers that provide feedback about products are not verified for the purchase or use of the product. Companies often order anonymous comments to form positive opinions about their products, or negative ones about competitors. Therefore, be guided by the information in the pharmacists' responses in the first place.

Specialists